Peptides for Gut Health: BPC-157, KPV, and Larazotide

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

BPC-157 is the most studied peptide for gut healing — it repairs intestinal lining, reduces inflammation, and accelerates recovery from gut injuries. KPV is an anti-inflammatory tripeptide derived from alpha-MSH. Larazotide targets tight junction proteins to reduce intestinal permeability.

The Gut-Peptide Connection

The gastrointestinal tract is one of the most peptide-rich environments in the body, with hundreds of endogenous peptides regulating everything from motility to immune function to mucosal integrity. Therapeutic peptides have shown remarkable promise for a wide range of gut conditions — from functional disorders like IBS to serious inflammatory conditions like Crohn's disease and ulcerative colitis.

BPC-157: The Gut Healing Peptide

BPC-157 was originally isolated from human gastric juice, and its gut-healing properties are among its most well-documented effects. In animal models, BPC-157 has demonstrated the ability to: accelerate healing of gastric and duodenal ulcers, repair damage to the intestinal lining caused by NSAIDs, alcohol, and chemotherapy agents, reduce intestinal inflammation, and normalize gut motility. For gut applications, BPC-157 can be administered orally (dissolved in water) or subcutaneously. Typical oral dosing: 250–500 mcg dissolved in water, taken on an empty stomach 30 minutes before meals.

KPV: Anti-Inflammatory Tripeptide

KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminal sequence of alpha-MSH. It exerts potent anti-inflammatory effects in the gut by inhibiting NF-κB signaling — a master regulator of inflammatory gene expression. Studies in animal models of colitis have shown KPV to significantly reduce mucosal inflammation and promote healing of the intestinal epithelium.

Larazotide (AT-1001): Targeting Tight Junctions

Larazotide acetate is an 8-amino acid peptide that targets zonulin — a protein that regulates the permeability of tight junctions between intestinal epithelial cells. Elevated zonulin levels are associated with increased intestinal permeability ("leaky gut"), which has been implicated in celiac disease, IBS, and inflammatory bowel disease. Clinical trials have shown larazotide to reduce intestinal permeability and improve symptoms in celiac disease patients.

Conclusion

Peptide-based gut therapy represents one of the most exciting frontiers in gastroenterology. The combination of targeted mechanisms, favorable safety profiles, and the ability to address root causes of gut dysfunction makes these peptides valuable tools in the management of a wide range of GI conditions.